Optimization of a synthetic β-catenin-dependent promoter for tumor-specific cancer gene therapy

Molecular Therapy

Volumn 10, Issue 1, 2004, Pages 150-161

  Lipinski, Kai S ^a   Djeha, Hakim A ^a   Gawn, Jonathan ^a   Cliffe, Suzanne ^a   Maitland, Norman J ^b   Palmer, Daniel H ^c   Mountain, Andrew ^a   Irvine, Alistair S ^a   Wrighton, Christopher J ^a,d  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF GRAZ   (Austria)

Author keywords

catenin; Adenovirus; Diphtheria toxin A; Gene therapy; Tcf; Wnt

Indexed keywords

ADENOVIRUS VECTOR; BETA CATENIN; DIPHTHERIA TOXIN; T CELL FACTOR PROTEIN;

ARTICLE; BINDING SITE; CANCER THERAPY; COLORECTAL CANCER; CONTROLLED STUDY; GENE ACTIVITY; GENE EXPRESSION; GENE THERAPY; GENETIC REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; PROMOTER REGION; PROSTATE CANCER; PROTEIN BINDING; REGULATORY MECHANISM; VIRAL GENE THERAPY; WILD TYPE;

ADENOVIRIDAE; BETA CATENIN; BINDING SITES; CARCINOMA; CELL LINE, TUMOR; CYTOSKELETAL PROTEINS; DIPHTHERIA TOXIN; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; NEOPLASMS; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; TATA BOX; TCF TRANSCRIPTION FACTORS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

ADENOVIRIDAE; ALOCASIA MACRORRHIZOS; GIBBON APE LEUKEMIA VIRUS; HYLOBATES SP.;

EID: 3042853832     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.03.021     Document Type: Article

References (49)

1. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat. Rev. Cancer 1 2001 131-141
2. Lundstrom K. Latest development in viral vectors for gene therapy Trends Biotechnol. 21 2003 117-122
3. Galanis E. Vile R. Russell S.J. Delivery systems intended for in vivo gene therapy: targeting and replication competent viral vectors Crit. Rev. Oncol. Hematol. 38 2001 177-192
4. Vile R.G. Russell S.J. Lemoine N.R. Cancer gene therapy: hard lessons and new courses Gene Ther. 7 2000 2-8
5. Bateman A. et al. Fusogenic membrane glycoproteins as novel class of genes for the local and immune-mediated control of tumor growth Cancer Res. 60 2000 1492-1497
6. van Beusechem V.W. van Rijswijk A.L. van Es H.H. Haisma H.J. Pinedo H.M. Gerritsen W.R. Recombinant adenovirus vectors with knobless fibers for targeted gene transfer Gene Ther. 7 2000 1940-1946
7. Kelly F.J. et al. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro Clin. Cancer Res. 6 2000 4323-4333
8. Haisma H.J. et al. Targeting of adenoviral vectors through a bispecific single-chain antibody Cancer Gene Ther. 7 2000 901-904
9. Wickham T.J. Targeting adenovirus Gene Ther. 7 2000 110-114
10. Miller N. Whelan J. Progress in transcriptionally targeted and regulatable vectors for genetic therapy Hum. Gene Ther. 8 1997 803-815
11. Nettelbeck D.M. Jerome V. Muller R. A strategy for enhancing the transcriptional activity of weak cell type-specific promoters Gene Ther. 5 1998 1656-1664
12. Lipinski K.S. Djeha A.H. Ismail T. Mountain A. Young L.S. Wrighton C.J. High-level, β-catenin/Tcf-dependent transgene expression in secondary colorectal cancer tissue Mol. Ther. 4 2001 365-371
13. Fodde R. Smits R. Clevers H. APC, signal transduction and genetic instability in colorectal cancer Nat. Rev. Cancer 1 2001 55-67
14. Stambolic V. PTEN: a new twist on β-catenin? Trends Pharmacol. Sci. 23 2002 104-106
15. de la Coste A. et al. Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas Proc. Natl. Acad. Sci. USA 95 1998 8847-8851
16. Satoh S. et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1 Nat. Genet. 24 2000 245-250
17. Brunori M. Malerba M. Kashiwazaki H. Iggo R. Replicating adenoviruses that target tumors with constitutive activation of the Wnt signaling pathway J. Virol. 75 2001 2857-2865
18. Fuerer C. Iggo R. Adenovirus with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the Wnt signalling pathway Gene Ther. 9 2002 270-281
19. Djeha A.H. et al. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954 Cancer Gene Ther. 7 2000 721-731
20. Djeha A.H. et al. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors Mol. Ther. 3 2001 233-240
21. Grove J.I. et al. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitisation to the prodrug CB1954 Cancer Res. 63 2003 5532-5537
22. Yamaizumi M. Mekada E. Uchida T. Okada Y. One molecule of Diphtheria toxin fragment A introduced into a cell can kill the cell Cell 15 1978 245-250
23. Rodriguez R. Lim H.-Y. Bartkowski L.M. Simons J.W. Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics Prostate 34 1998 259-269
24. van der Poel H.G. et al. A novel method for the determination of basal gene expression of tissue-specific promoters: an analysis of prostate-specific promoters Cancer Gene Ther. 8 2001 927-935
25. Babiss L.E. Friedman J.M. Darnell J.E.Jr. Cellular promoters incorporated into the adenovirus genome: effect of viral DNA replication on endogenous and exogenous gene transcription J. Mol. Biol. 193 1987 643-650
26. Imler J.L. et al. Targeting cell-specific gene expression with an adenovirus vector containing the lacZ gene under the control of the CFTR promoter Gene Ther. 3 1996 49-58
27. Ring C.J. Harris J.D. Hurst H.C. Lemoine N.R. Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter Gene Ther. 3 1996 1094-1103
28. Steinwaerder D.S. Lieber A. Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo Gene Ther. 7 2000 556-567
29. Shi Q. Wang Y. Worton R. Modulation of the specificity and activity of a cellular promoter in an adenoviral vector Hum. Gene Ther. 8 1997 403-410
30. Melcher A. Todryk S. Hardwick N. Ford M. Jacobson M. Vile R.G. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression Nat. Med. 4 1998 581-587
31. Park K.H. et al. Gene therapy with GM-CSF, interleukin-4 and herpes simplex virus thymidine kinase shows strong antitumor effect on lung cancer Anticancer Res. 23 2003 1559-1564
32. Melcher A. Bateman A. Harrington K. Ahmed A. Gough M. Vile R. Dendritic cells for the immunotherapy of cancer Clin. Oncol. 14 2002 185-192
33. Qiao J. Caruso M. PG13 packaging cells produce recombinant retrovirus carrying a diphtheria toxin mutant which kills cancer cells J. Virol. 76 2002 7343-7348
34. Li Y. et al. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer Cancer Res. 62 2002 2576-2582
35. Lee E.J. Jameson L. Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy Hum. Gene Ther. 13 2002 533-542
36. Rubinfeld B. Robbins P. El-Gamil M. Albert I. Porfiri E. Polakis P. Stabilization of β-catenin by genetic defects in melanoma cell lines Science 275 1997 1790-1792
37. Inagawa S. et al. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival Clin. Cancer Res. 8 2002 450-456
38. Lin S.-Y. et al. β-Catenin, a novel prognostic marker for breast cancer: its role in cyclin D1 expression and cancer progression Proc. Natl. Acad. Sci. USA 97 2000 4262-4266
39. Gamallo C. Palacios J. Moreno G. de Mora J.C. Suarez A. Armas A. β-Catenin expression pattern in stage I and II ovarian carcinomas: relationship with β-catenin gene mutations, clinicopathological features, and clinical outcome Am. J. Pathol. 155 1999 527-536
40. Chesire D.R. Ewing C.M. Sauvageot J. Bova G.S. Isaacs W.B. Detection and analysis of β-catenin mutations in prostate cancer Prostate 45 2000 323-334
41. Cairns P. et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer Cancer Res. 57 1997 4997-5000
42. Prieve M.G. Waterman M.L. Nuclear localization and formation of beta-catenin-lymphoid enhancer factor 1 complexes are not sufficient for activation of gene expression Mol. Cell. Biol. 19 1999 4503-4515
43. Yano H. et al. Differential expression of beta-catenin in human glioblastoma multiforme and normal brain tissue Neurol. Res. 22 2000 650-656
44. -/- colon carcinoma Science 275 1997 1784-1787
45. Kuddus R. Gu B. DeLuca N.A. Relationship between TATA-binding protein and herpes simplex virus type 1 ICP4 DNA-binding sites in complex formation and repression of transcription J. Virol. 69 1995 5568-5575
46. Dion V. Coulombe B. Interactions of a DNA-bound transcriptional activator with the TBP-TFIIA-TFIIB-promoter quaternary complex J. Biol. Chem. 278 2003 11495-11501
47. Keyvani K. Baur I. Paulus W. Tetracycline-controlled expression but not toxicity of an attenuated diphtheria toxin mutant Life Sci. 64 1999 1719-1724
48. Haines A.M. et al. CL22-a novel cationic peptide for efficient transfection of mammalian cells Gene Ther. 8 2001 99-110
49. Irvine A.S. et al. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization Nat. Biotechnol. 18 2000 1273-1278